O'Shaughnessy Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

O'Shaughnessy Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-351	Closed	-$32K	–	2196
2021 Q3	$32K	Sell	351 -3,667	-91%	-$331K	﹤0.01%	1805
2021 Q2	$383K	Buy	4,018 +6	+0.1%	+$625	0.01%	769
2021 Q1	$456K	Buy	4,012 +8	+0.2%	+$1.09K	0.01%	642
2020 Q4	$554K	Buy	4,004 +3,995	+44,389%	+$474K	0.02%	480
2020 Q3	$1K	Hold	9	–	–	﹤0.01%	1784
2020 Q2	$1K	Buy	+9	New	+$596	﹤0.01%	1645

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

O'Shaughnessy Asset Management's RARE Position: Q4 2021 in Review

O'Shaughnessy Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2021, closing a stake of 351 shares — an estimated $32K sold.

O'Shaughnessy Asset Management first reported a position in RARE in Q2 2020 and held it in 6 quarters. The position peaked at $554K in Q4 2020. 234 funds tracked by Wall St. Rank hold RARE as of Q4 2021.

O'Shaughnessy Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2021 after selling out during the quarter.
O'Shaughnessy Asset Management sold 351 Ultragenyx Pharmaceutical shares in Q4 2021, an estimated $32K.
O'Shaughnessy Asset Management first reported a position in Ultragenyx Pharmaceutical in Q2 2020 and held it in 6 quarters.
O'Shaughnessy Asset Management's Ultragenyx Pharmaceutical position peaked at $554K in Q4 2020.
234 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.